Skip to main content

Table 1 Anti-glycosaminoglycan antibody concentrations

From: Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis

Antibody (μg/mL)

Umbilical cord serum

Control serum

RA patients serum

 

Mean ± SEM

Mean ± SEM

Mean ± SEM

Anti-chondroitin sulphate A IgM

1.63 ± 0.3

750.95 ± 343.1

1225.27 ± 354.2

Anti-chondroitin sulphate B IgM

1.36 ± 0.2

608.00 ± 302.3

1300.61 ± 389.2

Anti-chondroitin sulphate C IgM

1.73 ± 0.4

673.70 ± 305.7

1964.34 ± 461.7

Anti-keratan sulphate IgM

1.63 ± 0.2

275.11 ± 184.5

836.87 ± 321.3

Anti-heparan sulphate IgM

2.27 ± 0.4

1115.91 ± 383.0

2605.36 ± 516.8

Anti-hyaluronic acid IgM

1.27 ± 0.2

4.32 ± 0.9

14.18 ± 4.5

Anti-chondroitin sulphate A IgG

1.54 ± 0.4

203.09 ± 89.1

872.79 ± 310.7

Anti-chondroitin sulphate B IgG

1.77 ± 0.8

508.07 ± 215.9

1551.62 ± 417.2

Anti-chondroitin sulphate C IgG

1.27 ± 0.1

241.53 ± 176.3

717.86 ± 273.3

Anti-keratan sulphate IgG

4.91 ± 4.3

1871.63 ± 481.1

2704.11 ± 525.2

Anti-heparan sulphate IgG

4.05 ± 3.8

1066.59 ± 326.7

2689.71 ± 515.8

Anti-hyaluronic acid IgG

1.09 ± 0.2

960.93 ± 365.3

1227.82 ± 379.3

  1. Mean antibody concentrations are expressed in μg/mL. The difference between serum anti-glycosaminoglycan (GAG) antibody levels of controls and umbilical cord samples was significant (three-way analysis of variance [ANOVA], F = 110.70; DF = 1.77; p < 0.001). The difference between RA patients and adult controls was also highly significant (three-factor ANOVA, F = 30.17 DF = 1.11 p < 0.001), and independent from type of the antigen and from the type of the antibody as well.